What is the current market price of Polatuzumab?

Polatuzumab is an innovative antibody drug conjugate (ADC) mainly used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma). Its unique mechanism is to specifically target the CD79b antigen on the B cell surface through a monoclonal antibody, and couple the cytotoxic drug to the antibody, so that the drug can accurately enter tumor cells, thereby killing cancer cells while reducing damage to normal cells. Compared with traditional chemotherapy, vepotuzumab has obvious advantages in efficacy and tolerability, and is an important option for patients with advanced disease or who have failed multiple lines of treatment.

In the domestic market, vepotuzumab has been approved for marketing and included in the medical insurance reimbursement system, greatly improving patient accessibility. The specifications currently on the market in China are 30mg injections, with the price of each injection being approximately RMB 10,000. In actual use, the patient's medical insurance reimbursement ratio will vary depending on the region and medical insurance policy. For specific prices, please consult the local medical insurance department. The price of drugs of the same specifications in overseas markets is approximately US$3,900, which is significantly higher than the domestic price in RMB equivalent. However, in clinical applications in Europe, the United States and some Asian countries, vepotuzumab has been widely verified for its anti-tumor efficacy.

It is worth noting that there are currently no generic drugs of vepotuzumab on the market, which means that its drug supply mainly relies on the original manufacturer. Original drugs must strictly follow GMP standards during the production process to ensure drug stability and safety. With the accumulation of domestic clinical experience, doctors can formulate treatment plans more scientifically so that patients can receive personalized anti-tumor treatment.

Overall, vepotuzumab, as a targeted antibody-drug conjugate, has shown good results in the treatment of relapsed or refractoryDLBCL. It is launched in China and included in medical insurance, making it possible for patients to obtain the drug within an affordable range. Its precise targeting mechanism and innovative pharmacological characteristics bring new options for lymphoma treatment.

Reference materials:https://www.drugs.com/polivy.html